Key Points {#FPar1}
==========

Omega-3 products are available as dietary supplements and prescription formulations; products containing docosahexaenoic acid (DHA) may have the unwanted effect of raising low-density lipoprotein cholesterol (LDL-C).Dietary supplements are not over-the-counter (OTC) products, and efficacy, quality, and safety of omega-3 dietary supplements are questionable because of a lack of regulation and potential content variability; currently, there are no approved OTC omega-3 fatty acid products.Omega-3 dietary supplements are not appropriate for the treatment of disease and are not therapeutically equivalent to, and should not be substituted for, prescription omega-3 fatty acid products; prescription products containing DHA should not be substituted for icosapent ethyl (highly purified eicosapentaenoic acid \[EPA\]).

Introduction {#Sec1}
============

For more than 35 years, omega-3 fatty acids have been thought to provide cardiovascular benefits, beginning with epidemiologic studies linking high omega-3 fatty acid dietary intake with reduced rates of cardiovascular disease in Greenland Inuits \[[@CR1]--[@CR3]\]. Subsequent diet-based studies suggested that increased omega-3 fatty acid consumption reduced cardiovascular mortality in high-risk (but not low-risk) individuals \[[@CR4]\]. Stemming from these and other findings, numerous fish oil dietary supplements containing omega-3 fatty acids have become commercially available.

Over the last decade, several prescription omega-3 fatty acid products have been approved by the US FDA based on clinical intervention trials. Dietary supplements of other classes of omega-3 fatty acid products are widely available, but there are no FDA-approved over-the-counter (OTC) omega-3 fatty acid drugs. This article provides an overview of the basic biochemistry and potential cardiovascular benefits of omega-3 fatty acids and compares omega-3 fatty acid prescription products and fish oil dietary supplements, highlighting key considerations for their clinical use.

Overview of Fatty Acid Biochemistry {#Sec2}
===================================

Fatty acids are carboxylic acids; they have a carboxyl group (COOH) at one end, they contain long carbon chains, and most have an even number of carbon atoms. The nomenclature for fatty acids takes into account whether the molecule contains double bonds: saturated fatty acids have no double bonds (thus the carbon atoms are "saturated" with hydrogen), whereas polyunsaturated fatty acids have multiple double bonds. The full name begins with the number of carbon atoms, followed by the number of double bonds. For those with double bonds, the location of the first double bond (counting from the methyl \[CH3\] end) is also defined in the nomenclature, using "n-x" or "omega-x" \[[@CR5], [@CR6]\]. As shown in Fig. [1](#Fig1){ref-type="fig"}, polyunsaturated fatty acids that have the first double bond in the third position (counting from the methyl end) belong to the n-3 (omega-3) family and include α-linolenic acid (ALA; 18:3, n-3), eicosapentaenoic acid (EPA; 20:5, n-3), and docosahexaenoic acid (DHA; 22:6, n-3); those that have the first double bond in the sixth position (counting from the methyl end) belong to the n-6 (omega-6) family and include linoleic acid (LA; 18:2, n-6) and arachidonic acid (AA; 20:4, n-6).Fig. 1Structures of omega-3 fatty acids. Both omega-6 and omega-3 fatty acids are polyunsaturated fatty acids, meaning that the hydrocarbon chain contains multiple double bonds. The naming convention is \[number of carbon atoms\]:\[number of double bonds\], n- (or ω)-\[position of first double bond starting from the methyl end of the chain, shown in *red*\]. Omega-3 fatty acids generally have anti-inflammatory and anti-thrombotic properties, whereas omega-6 fatty acids generally have pro-inflammatory and pro-thrombotic properties

Some fatty acids are considered essential because they are required for good health but cannot be synthesized in sufficient quantities by the body and therefore must be obtained in the diet. ALA and LA are essential fatty acids and precursors of key n-3 and n-6 fatty acids \[[@CR7], [@CR8]\]. Certain oils (e.g., flaxseed, canola) are high in ALA, which is a precursor of the longer-chain omega-3 fatty acids, including EPA and DHA (Fig. [1](#Fig1){ref-type="fig"}). However, the conversion of ALA into EPA and DHA is not very efficient in humans \[[@CR8]\]. Fish are good sources of EPA and DHA because fish consume algae that produce EPA and DHA \[[@CR8]\] or are predators of other fish that consume algae. While EPA and DHA are structurally and chemically distinct, DHA can be derived from EPA \[[@CR7]--[@CR9]\]. Other oils (e.g., corn, safflower, sunflower) are high in the omega-6 fatty acid LA, which is the precursor of AA.

Fatty acids are key components of both triglycerides and membrane phospholipids; triglycerides contain a glycerol backbone that is esterified to three fatty acids. Phospholipids containing a glycerol backbone are known as phosphoglycerides and are similar to triglycerides, but one of the three fatty acids is replaced by a phosphate group (Fig. [2](#Fig2){ref-type="fig"}). When fatty acids are not attached to other molecules, they are known as free fatty acids. Omega-3 and omega-6 fatty acids are incorporated into membrane phospholipids, where they alter the physical properties of cellular membranes and serve as precursors for several classes of lipid mediators \[[@CR7], [@CR8]\]. The relative amount, not the absolute amount, of these polyunsaturated fatty acids is key, because EPA and DHA compete with AA for the second carbon, or "sn-2," position in membrane phospholipids \[[@CR7]\]. When cells are exposed to inflammatory stimuli, the enzyme phospholipase A~2~ acts to release the incorporated polyunsaturated fatty acids from the sn-2 position of the phospholipid. The fatty acids are then converted by cyclooxygenase into eicosanoid-signaling molecules \[[@CR9]\]. AA is converted into eicosanoids that generally have pro-inflammatory or pro-thrombotic effects, whereas those derived from EPA typically have anti-inflammatory or anti-thrombotic effects \[[@CR6], [@CR9]\].Fig. 2Omega-3 fatty acids are components of triglycerides and phospholipids, and may also be found as free fatty acids. *Star* indicates sn-2 position; phospholipase A~2~ releases fatty acids from the sn-2 position of membrane phospholipids

Cardiovascular Benefits of Omega-3 Fatty Acids {#Sec3}
==============================================

The omega-3 fatty acids EPA and DHA are generally effective in reducing triglycerides and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with hypertriglyceridemia; these effects are observed with monotherapy and when administered in combination with a statin \[[@CR10]--[@CR16]\]. However, EPA and DHA may have differential effects on low-density lipoprotein cholesterol (LDL-C). DHA may raise LDL-C, whereas EPA has a neutral effect or may slightly lower LDL-C \[[@CR17], [@CR18]\]. The effect of DHA on LDL-C may be attributed in part to findings that DHA may downregulate the LDL receptor \[[@CR19], [@CR20]\].

The benefit of reducing triglycerides on cardiovascular outcomes remains to be conclusively proven, but emerging evidence from genetic studies suggests that triglycerides and triglyceride-rich lipoproteins play a causal role in coronary atherosclerosis \[[@CR21]--[@CR26]\]. In two independent studies of large US and Danish cohorts, individuals with life-long low triglycerides due to mutations in the apolipoprotein C3 (*APOC3*) gene had approximately 40 % lower coronary heart disease (CHD) risk than individuals with normal *APOC3* alleles \[[@CR21], [@CR22]\]. In the Danish cohort, this association was attenuated by adjusting for non-fasting triglycerides, implying that the effect of *APOC3* on triglycerides was at least partially responsible for the lowered CHD risk \[[@CR23]\]. ApoC-III is a protein coded by the *APOC3* gene that is part of the very-low-density lipoprotein complex and inhibits lipases, thus decreasing the uptake of triglyceride-rich lipoprotein particles \[[@CR23]\]. More recently, genetic studies have revealed that inactivating mutations in the gene encoding ANGPTL4 (a regulatory factor in triglyceride metabolism) are associated with lower triglyceride levels and lower risk of coronary artery disease \[[@CR25], [@CR26]\].

The potential cardiovascular benefits of omega-3 fatty acids are not restricted to their effects on lipids. Omega-3 fatty acids, particularly EPA, have pleiotropic effects at multiple steps involved in atherosclerosis \[[@CR27], [@CR28]\]. For example, EPA has beneficial effects on endothelial function \[[@CR29], [@CR30]\] by improving the balance between the vasodilator nitric oxide and damaging reactive oxygen species \[[@CR31]\]. EPA has been shown to have beneficial effects on monocyte migration and subsequent differentiation into macrophages and foam cells, which are key steps in early atherosclerotic lesion development \[[@CR32]--[@CR35]\]. Atherosclerosis is a chronic inflammatory disease \[[@CR36]--[@CR38]\] and EPA may reduce the components of inflammation via beneficial effects on eicosanoids, as discussed earlier \[[@CR6], [@CR9]\], and by altering pro-inflammatory cytokine levels \[[@CR39], [@CR40]\]. EPA has also been shown to reduce plaque volume and carotid intima-media thickness, suggesting it may influence plaque formation and progression \[[@CR41]--[@CR46]\]. Finally, the omega-3 fatty acids reduce adenosine diphosphate--induced platelet aggregation, suggesting the potential for limiting thrombus formation following plaque rupture \[[@CR47]\].

Prescription Omega-3 Fatty Acid Products {#Sec4}
========================================

Several omega-3 fatty acid prescription products have been approved by the FDA for use as an adjunct to diet for reducing triglycerides in adults with severe hypertriglyceridemia (triglycerides ≥500 mg/dl) (Table [1](#Tab1){ref-type="table"}). These include products containing both EPA and DHA (Lovaza^®^ \[omega-3-acid ethyl esters\], GlaxoSmithKline, Research Triangle Park, NC, USA; Omtryg^®^ \[omega-3-acid ethyl esters A\], Trygg Pharma, Inc, Arlington, VA, USA; Epanova^®^ \[omega-3-carboxylic acids\], AstraZeneca Pharmaceuticals, Wilmington, DE, USA; and generic Lovaza formulations) \[[@CR48]--[@CR52]\]. Omega-3-acid ethyl esters \[[@CR48]\] and omega-3-acid ethyl esters A \[[@CR49]\] contain omega-3-acid ethyl esters, whereas the omega-3-carboxylic acids product is a fish oil-derived mixture of polyunsaturated free fatty acids, including omega-3 fatty acids, the most abundant of which are EPA and DHA \[[@CR13], [@CR50], [@CR53]\]. There is one FDA-approved EPA-only product: a high-purity formulation containing icosapent ethyl, the ethyl ester of EPA (Vascepa^®^, Amarin Pharma, Inc, Bedminster, NJ, USA); it does not contain DHA or any other omega-3 fatty acid \[[@CR54]\].Table 1US FDA-approved prescription omega-3 fatty acid products indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dl) hypertriglyceridemiaBrand nameGeneric nameEPA content^a^DHA content^a^Dosing/administrationAdverse reactions in clinical trialsVascepaIcosapent ethyl1 gNone4 g/day (2 capsules bid) with foodArthralgia,^b^ oropharyngeal painLovaza^c^Omega-3-acid ethyl esters\~0.465 g\~0.375 g4 g/day (4 capsules od or 2 capsules bid) with or without foodEructation,^d^ dyspepsia,^d^ taste perversion,^d^ constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rashEpanova^e^Omega-3-carboxylic acids0.55 g0.2 g2 g or 4 g/day (2 or 4 capsules od). In clinical trials, administration took place without regard to mealsDiarrhea,^d^ nausea,^d^ abdominal pain or discomfort,^d^ eructation,^d^ abdominal distension, constipation, vomiting, fatigue, nasopharyngitis, arthralgia, dysgeusiaOmtrygOmega-3-acid ethyl esters A\~0.465 g\~0.375 g4 g/day (4 capsules od or 2 capsules bid) with foodEructation,^d^ dyspepsia,^d^ taste perversion,^d^ constipation, GI disorder, vomiting, increased ALT/AST, pruritus, rash*ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *bid* twice daily, *DHA* docosahexaenoic acid, *EPA* eicosapentaenoic acid, *GI* gastrointestinal, *od* once daily^a^Per capsule^b^Incidence ≥2 % and \>placebo^c^Generic formulations of Lovaza are available^d^Incidence ≥3 % and \>placebo^e^Epanova is approved but not available at the time of the writing of this review

The safety and lipid-lowering efficacy of the prescription omega-3 fatty acid products have been evaluated in randomized, blinded, placebo-controlled trials of patients with very high baseline triglycerides (≥500 mg/dl) (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR10]--[@CR13], [@CR48]--[@CR50], [@CR54]\] and patients with residually high triglycerides (≥200 to \<500 mg/dl) despite statin therapy (Table [2](#Tab2){ref-type="table"}) \[[@CR14]--[@CR16], [@CR48]\]. In addition to the reductions in triglycerides, non-HDL-C, and total cholesterol observed across these clinical trials, it is notable that increases in LDL-C compared with placebo were observed for trials of products containing DHA and EPA but not for trials of the EPA-only product, icosapent ethyl (Fig. [3](#Fig3){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Also notable is the finding that higher baseline triglycerides were generally associated with greater triglyceride reductions \[[@CR12], [@CR18], [@CR55]\]. Thus, it is expected that the differences in the magnitude of triglyceride reductions observed across clinical trials of prescription omega-3 fatty acid products shown in Table [2](#Tab2){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"} are reflections of differences in patient baseline triglycerides. All of the prescription omega-3 fatty acid products have been generally well tolerated in clinical trials and have well-established safety and tolerability profiles. The most common adverse events for the prescription omega-3 fatty acid products are provided in Table [1](#Tab1){ref-type="table"} \[[@CR48]--[@CR52], [@CR54]\]. Notably, the most common adverse events occurring with prescription products containing DHA and EPA were predominantly gastrointestinal, but not with the EPA-only product, icosapent ethyl (Table [1](#Tab1){ref-type="table"}). Use of products containing both DHA and EPA also require periodic monitoring of LDL-C during therapy due to the potential for increases in this lipid parameter, while treatment with the EPA-only product, icosapent ethyl, has no LDL-C monitoring requirement \[[@CR48]--[@CR50], [@CR54]\].Fig. 3Percentage change from baseline versus placebo in key lipid parameters from clinical trials of prescription omega-3 fatty acid products (4 g/day) in patients with very high triglycerides (≥500 mg/dl) \[[@CR48]--[@CR50], [@CR54]\]. Upper limit for triglycerides was 2000 mg/dl in studies of omega-3-acid ethyl esters, omega-3-carboxylic acids, and icosapent ethyl and 1500 mg in the omega-3-acid ethyl esters A study. Omega-3-acid ethyl esters values are based on pooled data from two studies \[[@CR10], [@CR11]\] (6 and 16 weeks' duration) as reported in the omega-3-acid ethyl esters prescribing information \[[@CR48]\]. Icosapent ethyl data are from the MARINE (Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study with an Open-Label Extension) study (12 weeks) \[[@CR12]\]. Omega-3-acid ethyl esters A data (12 weeks) have only been published in the product's prescribing information \[[@CR49]\]. Omega-3-carboxylic acids data are from the EVOLVE (Epanova for Lowering Very High Triglycerides) study (12 weeks) \[[@CR13]\]. Difference versus placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change---placebo median % change; icosapent ethyl = median of \[icosapent ethyl % change---placebo % change\] (Hodges--Lehmann estimate); omega-3-acid ethyl esters A = Hodges--Lehmann median of all pairwise differences from placebo; omega-3-carboxylic acids = median of \[omega-3-carboxylic acids % change---placebo % change\] (Hodges--Lehmann estimate). *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *TC* total cholesterol, *TG* triglyceridesTable 2Effects of omega-3 fatty acids (4 g/day) added to statin therapy on key lipid parameters in patients with high triglyceride levels at baseline (≥200 and \<500 mg/dl)^a^ParameterCOMBOS study \[[@CR14], [@CR48]\] (8 weeks)ANCHOR study \[[@CR15]\] (12 weeks)ESPRIT study \[[@CR16]\] (6 weeks)Omega-3-acid ethyl esters^b^ + statin^c^ (*n* = 122)Placebo + statin^c^ (*n* = 132)Icosapent ethyl + statin^d^ (*n* = 226)Placebo + statin^d^ (*n* = 227)Omega-3-carboxylic acids + statin^e^ (*n* = 207)Placebo + statin^e^ (*n* = 211)TG Baseline level (mg/dl)268271265259287280 % change from baseline−30−6−18+6−21−8 % difference vs. placebo−23^f^ (*p* \< 0.0001)−22^f^ (*p* \< 0.0001)NR (*p* \< 0.001)Total cholesterol Baseline level (mg/dl)184184167168178174 % change from baseline−5−2−3+9−4+0.5 % difference vs. placebo--3^f^ (*p* \< 0.05)--12^f^ (*p* \< 0.0001)NR (*p* \< 0.001)Non-HDL-C Baseline level (mg/dl)137141128128139135 % change from baseline−9−2−5+10−7−0.9 % difference vs. placebo−7^f^ (*p* \< 0.0001)−14^f^ (*p* \< 0.0001)NR (*p* \< 0.001)LDL-C Baseline level (mg/dl)918882849492 % change from baseline+0.7−3+2+9+1+1 % difference vs. placebo+4^f^ (*p* = 0.05)--6^f^ (*p* = 0.0067)NR (NS)HDL-C Baseline level (mg/dl)464337393939 % change from baseline+3−1−1+5+3+2 % difference vs. placebo+5^f^ (*p* \< 0.05)−5^f^ (*p* = 0.0013)NR (NS)*COMBOS* Combination of Prescription Omega-3 with Simvastatin study, *ESPRIT* Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol study, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *NCEP ATP* III National Cholesterol Education Program Adult Treatment Panel III, *NR* not reported, *NS* not significant (*p* \> 0.05), *TG* triglycerides^a^Additional lipid inclusion criteria: COMBOS, mean LDL-C ≤10 % above NCEP ATP III goal; ANCHOR, LDL-C ≥40 and \<100 mg/dl on optimized statin therapy, with criteria later expanded to mean of 2 TG-qualifying values ≥185 mg/dl with at least 1 value ≥200 mg/dl and upper limit of LDL-C ≤115 mg/dl; ESPRIT, LDL-C at ≤110 % of NCEP ATP III goal or on maximally tolerated statin dose^b^In 2014, data regarding patients with TG levels 200--499 mg/dl was removed from the prescribing information^c^Simvastatin 40 mg/dl^d^Stable statin therapy with atorvastatin, rosuvastatin, or simvastatin^e^Stable statin therapy with lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, or rosuvastatin^f^Difference vs. placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change---placebo median % change; icosapent ethyl = median of (icosapent ethyl % change---placebo % change) (Hodges--Lehmann estimate)

Omega-3 Fatty Acid Dietary Supplements {#Sec5}
======================================

Several types of dietary supplements containing omega-3 fatty acids are available, including fish oils, krill oils, algal oils, and plant oils (Table [3](#Tab3){ref-type="table"}). Except for plant sources (e.g., soybeans, walnuts, and canola oil, which contain ALA), all contain a mixture of EPA and DHA, but may also include saturated fats, other lipids, and potentially harmful ingredients \[[@CR56]--[@CR62]\]. These products are widely available in drug and health food stores, with more than 300 "omega-3" products listed in the US National Institutes of Health Dietary Supplement Label Database \[[@CR63]\].Table 3Non-prescription omega-3 fatty acid products: dietary supplementsProductsMore than 300 products availableFormulationsSoft gels, liquids, powders, gummiesSourcesFish oils, krill oils, algal oils, plant oilsOmega-3 fatty acid content and purityPredominantly DHA + EPA in varying quantities; DHA may raise LDL-C levels\
May contain inconsistent DHA/EPA levels\
May contain saturated fat, cholesterol, oxidation products, and/or other contaminants that may have adverse health effectsRegulatory requirementsNot required to demonstrate efficacy or safety prior to marketing\
Should not be substituted for prescription omega-3 fatty acid products\
Dietary supplements are not OTC drugs; no OTC omega-3 fatty acid or fish oil products are approved or available*DHA* docosahexaenoic acid, *EPA* eicosapentaenoic acid, *LDL-C* low-density lipoprotein cholesterol, *OTC* over the counter

Although the widely available omega-3 fatty acid dietary supplements can be obtained without a prescription, it is important to understand that they are not OTC drugs. It is a common misconception among physicians, pharmacists, and patients that omega-3 fatty acid dietary supplements are FDA-approved OTC drugs. As per the Dietary Supplement Health and Education Act (DSHEA) of 1994, dietary supplements are not considered drugs for purposes of FDA regulation, and therefore are not subject to the same regulatory oversight as prescription or OTC drugs \[[@CR64]\]. As such, dietary supplements are not required to demonstrate safety prior to marketing \[[@CR65]\]. Moreover, dietary supplements do not require pre-marketing approval from the FDA, and, under the DSHEA of 1994, anything labeled as a dietary supplement is assumed to be safe until proven otherwise. Importantly, it has been suggested that physicians and patients cannot be assured that dietary supplements are safe without sweeping legal and regulatory changes \[[@CR66]\]. No OTC omega-3 fatty acid products are currently approved or available in the USA.

There are issues and concerns regarding the content, quality, and purity of omega-3 fatty acid dietary supplements. It is important to recognize that dietary supplements do not always contain what is specified on their label and may differ in EPA and DHA content from batch to batch \[[@CR62], [@CR67]--[@CR69]\]. For example, analytic studies have reported actual EPA and DHA concentrations in dietary supplements sold in the USA ranging from 51 to 124 % (EPA) and from 61 to 153 % (DHA) of the amounts stated on the product labels \[[@CR62]\]. More recent studies have confirmed these findings (range 66--184 % \[EPA\] and 62--184 % \[DHA\] of the stated label amounts), with 74 % of supplements tested containing less than 100 % of the stated amounts and 16 % of supplements containing less than 80 % of the stated amounts \[[@CR67]\]. In a recent study of fish oil supplements marketed in New Zealand, two-thirds of supplements tested contained less than 67 % of the stated amounts of EPA and DHA, with 2 of 32 supplements containing only one-third of the stated label amounts \[[@CR68]\]. Supplements have also been reported to meet total EPA + DHA content claimed on the label but not stated levels of individual components (i.e., lower EPA content and higher DHA content than stated on the label) \[[@CR69]\].

Regarding additional ingredients found in omega-3 fatty acid dietary supplements, one study specifically testing the contents found that half of the samples tested provided 30--50 % of recommended daily cholesterol intake at a dose of 3.4 g EPA/DHA, and two-thirds of the products provided at least 2.5 g of saturated fats \[[@CR61]\]. Some omega-3 fatty acid dietary supplements have also been found to be highly oxidized. Omega-3 fatty acids are highly prone to oxidation because of the double bonds within the fatty acid chain, leaving fewer non-oxidized fatty acids for therapeutic benefit and replacing them with a complex mixture of lipid peroxides and secondary oxidation products \[[@CR68]\]. In product testing, only 8 % of fish oil supplements met all international recommendations for levels of oxidation markers, and the safety of these oxidation products has not been well investigated \[[@CR68], [@CR70]\]. Testing of 171 Canadian omega-3 fatty acid dietary supplements revealed that 50 % of products failed at least one of the voluntary safety standards recommended for product oxidation \[[@CR71]\]. Recent data have demonstrated that oxidation products found in dietary supplements can interfere with the ability of omega-3 fatty acids to inhibit human small, dense LDL oxidation and hence may interfere with their potential biological benefits \[[@CR72]\]. A review of the literature found that oxidized lipids can be absorbed and metabolized and alter cholesterol metabolism in multiple models by increasing cholesterol uptake by macrophages, decreasing cholesterol re-uptake in the liver, and increasing total cholesterol levels \[[@CR73]\]. Oxidized lipids were also noted to adversely affect markers of oxidative stress and to cause pro-inflammatory effects in animal and human studies, leading the authors of those studies to conclude that oxidized lipids have the potential to increase the risk of atherosclerosis and thrombosis \[[@CR73]\]. Taken together, the data on the purity and content of omega-3 fatty acid dietary supplements coupled with the lack of regulation regarding these products shed light upon the fact that omega-3 fatty acid dietary supplements are not being adequately monitored by manufacturers or government agencies.

In addition to all of the content variability and safety issues discussed above, one further aspect hindering the therapeutic use of omega-3 fatty acid dietary supplements is that dietary supplements may require a high pill burden to achieve the dose levels found in prescription products, which in turn may adversely impact treatment adherence \[[@CR74], [@CR75]\].

Discussion {#Sec6}
==========

The average patient is exposed to numerous sources of information about their healthcare, often only remembering the information that resonates. The concept that a deficiency of a substance can lead to illness or disease harkens back to the discovery of vitamins in the 19th century. Subsequently, this concept has led to purported "miracle" cures and unsubstantiated claims of benefit from thousands of supplement and nutraceutical manufacturers. It is the role of the clinician to review data or lack thereof when discussing supplements with their patients. The indication for use of prescription omega-3 products should be reviewed with the patient along with the product's benefits, safety, and the difference between the prescription product and dietary supplements.

As their name indicates, dietary supplements are only appropriate to supplement the diet. They contain low doses of omega-3 fatty acids that are inappropriate for treating disease. Further, the doses found in omega-3 fatty acid dietary supplements may not be consistent with those specified on the label. Lack of regulation and product quality control may also be responsible for the noted issues of batch-to-batch variability and presence of contaminating ingredients in omega-3 fatty acid dietary supplements, which may also impact proper dosing and potentially safety. The low doses found in dietary supplements may not be sufficient for addressing cardiovascular risk, and professional organizations have been moving away from recommending these low-dose supplements for cardiovascular protection \[[@CR76], [@CR77]\]. However, the triglyceride-lowering efficacy of prescription omega-3 fatty acids has been shown to be dose-dependent \[[@CR12], [@CR13], [@CR15], [@CR16], [@CR78]\]. Thus, patients attempting to administer doses of omega-3 fatty acid dietary supplements to achieve the level of omega-3 fatty acids in prescription products---and, potentially, their desired effects---would need to consume a higher number of capsules than with prescription products. For these reasons, it is important for primary care physicians to understand and educate their patients that omega-3 fatty acid dietary supplements are not approved or intended to treat disease and should not be substituted for prescription products. As cost concerns may sometimes lead to inappropriate substitution of omega-3 fatty acid dietary supplements for prescription products, it may be worth noting that patient discount programs exist for some prescription omega-3 fatty acid products. At the same time, it is equally important that prescription products containing both DHA and EPA not be substituted for the purified EPA product icosapent ethyl, given that DHA may raise LDL-C and complicate the treatment of patients with dyslipidemia. Per FDA equivalence codes, pure EPA is not therapeutically equivalent to DHA-containing products \[[@CR79]\].

Although statin therapy significantly reduces cardiovascular events and mortality, elevated triglycerides and residual cardiovascular risk remain in patients with dyslipidemia despite well-controlled LDL-C \[[@CR80]\]. Thus, there is a need for adjunctive therapy to reduce this risk. In the JELIS study of hypercholesterolemic Japanese patients, major coronary events were significantly reduced in patients treated with EPA plus a statin compared with patients receiving only statin therapy (relative risk reduction of 19 % in the EPA group, *p* = 0.011) \[[@CR81]\]. More recently, clinical trials of ezetimibe (IMPROVE-IT \[[@CR82]\]) and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors (OSLER study \[[@CR83]\] and ODYSSEY LONG TERM study \[[@CR84]\]) have confirmed or suggested that statin add-on therapy may be effective in further reducing residual cardiovascular risk. These studies emphasize that "lower LDL-C is better," and that more can be done for statin-treated patients to address residual cardiovascular risk \[[@CR85]\].

Given the multiple beneficial effects of omega-3 fatty acids, it is reasonable to consider adding a prescription omega-3 fatty acid to a statin to help address residual cardiovascular risk. However, previous clinical outcome studies with products containing omega-3 fatty acids have produced inconsistent results. Some trials showed significant improvements in clinical outcomes \[[@CR81], [@CR86], [@CR87]\], whereas others did not \[[@CR88]--[@CR91]\]. These disappointing results may be explained in part by insufficient doses of omega-3 fatty acids and/or powering of studies, thus emphasizing the potential need for high-purity, prescription-strength dosing and adequately powered studies. Two ongoing clinical outcome trials are addressing these issues and are using high-dose prescription omega-3 fatty acids. REDUCE-IT is comparing icosapent ethyl plus statin versus placebo plus statin in patients aged ≥45 years who have hypertriglyceridemia after receiving statin therapy for at least 4 weeks, and who have established, or a high risk of, cardiovascular disease \[[@CR92]\]. STRENGTH is comparing omega-3-carboxylic acids plus statin versus placebo plus statin in adults with LDL-C \<100 mg/dl, high triglycerides, and low HDL after at least 4 weeks of statin therapy, and who are at high risk of a future cardiovascular event \[[@CR93]\]. The results of these trials will help define the role of prescription omega-3 fatty acid products as add-on therapy to statins in addressing the residual cardiovascular risk in patients receiving statin therapy.

Conclusions {#Sec7}
===========

Prescription omega-3 fatty acid products have proven safety and lipid-lowering efficacy and can be prescribed with confidence to patients with elevated triglycerides, including those who are already receiving a statin. In contrast, dietary supplements are not OTC drugs, and therefore are not required to have a proven safety and efficacy profile. Dietary supplements are highly variable in omega-3 fatty acid content and doses between brands, and, for some products, even between batches. They may also contain additional ingredients that could counter potential benefits. Accordingly, they should not be substituted for prescription products. Similarly, prescription products containing DHA and EPA should not be substituted for a purified EPA product, because products that contain DHA may raise LDL-C, thereby confounding treatment of patients with dyslipidemia.
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